Featured content in this Issue:
Public and Industry Respond to DEA’s Renewed Plan to Place DOI and DOC in Schedule I
Updates on State Psychedelics Programs
Fourth Time Lucky for California Psychedelic Policy Reform?
Backlash in Oregon; Updated Oregon Psilocybin Services Rules
Colorado Natural Medicine Updates
Mass. Legislature Considers Legal Psychedelics
TARA Mind Scores $8M Seed Round
No New Psychiatric Drugs for Europeans in 2023
Hallucinogen-Associated ER Visits
Companies, organisations and drug candidates mentioned in this Bulletin include: atai Life Sciences, TARA Mind, GH Research, Cybin, Psilera, Incannex.
This is the first issue of our Psychedelic Bulletin that’s exclusively for Pα+ subscribers. Head to our Join page to learn more, or sign in to your account.
